PEAK6 Investments’s Lifecore Biomedical LFCR Stock Holding History

PEAK6 Investments’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-38,000	Closed	-$440K	–	6319
2022 Q1	$440K	Buy	+38,000	New	+$423K	﹤0.01%	3270

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

PEAK6 Investments's LFCR Position: Q3 2023 in Review

PEAK6 Investments sold out of Lifecore Biomedical (LFCR) in Q3 2023, closing a stake of 18,524 shares — an estimated $179K sold.

PEAK6 Investments first reported a position in LFCR in Q2 2022 and held it in 2 quarters. The position peaked at $179K in Q2 2023. 69 funds tracked by Wall St. Rank hold LFCR as of Q3 2023.

PEAK6 Investments reported no remaining Lifecore Biomedical position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 18,524 Lifecore Biomedical shares in Q3 2023, an estimated $179K.
PEAK6 Investments first reported a position in Lifecore Biomedical in Q2 2022 and held it in 2 quarters.
PEAK6 Investments's Lifecore Biomedical position peaked at $179K in Q2 2023.
69 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.